№ 123 · biology

CRISPR: what it cuts, what is approved, and why the germline fight is real

A reader asked three things about CRISPR: what it actually cuts, what has been approved, and why the fight over editing the germline is real. The short answers: it cuts both strands of DNA at a spot picked by a 20-letter guide, and the cell does the editing. One CRISPR medicine is approved in the US, for two blood disorders. The germline fight is real because an edit to an embryo goes on to every cell of a child and to that child's children.

A search tool borrowed from bacteria

CRISPR began as a bacterial immune system. Bacteria that survive a virus store short snippets of its DNA in their own genome. Those snippets are copied into RNA, and an enzyme called Cas9 uses that RNA to find DNA with the matching letters and cut it, so a returning virus is chopped up. Emmanuelle Charpentier's group found the second RNA the system needs in 2011. In 2012 she and Jennifer Doudna's group showed that the two RNAs can be joined into one guide, and that changing the guide's 20 matching letters points Cas9 at any DNA you choose, as long as it sits next to a short tag described below. The two shared the 2020 Nobel Prize in Chemistry for it.

What it actually cuts

Cas9 does not read the guide against the whole genome at once. It first looks for a short tag, three letters ending in GG for the commonly used Cas9, called the PAM. Only next to a PAM does it open the DNA and check whether the 20 letters there pair with the guide. The letters nearest the PAM, the seed, matter most. In the 2012 paper's test on one target, at least 13 matching letters next to the PAM were needed for efficient cutting, while up to six mismatches at the far end were tolerated. That tolerance is why CRISPR can cut the wrong place: a stretch of genome that matches the seed may be cut even though it differs elsewhere.

When the match holds, Cas9 cuts both strands, three letters from the PAM. That is the whole of what Cas9 does. The edit comes from how the cell mends the break. One way is simply to glue the ends back together, which usually adds or loses a few letters and can break the gene. If the cell is also given a piece of DNA that matches the stretch around the cut, it can copy from that piece instead, writing a chosen change. Newer variants, base editors and prime editors, cut only one strand and change letters without a full break.

Interactive Click any letter of the DNA (or tab to it and press Enter) to change it, or pick a preset. The readout says whether Cas9 would cut under a simple rule drawn from the 2012 paper, and where.

Our own drawing, not a figure from any source. The guide is RNA; it is shown here in DNA letters (T for U) so it can be compared letter by letter with the DNA strand that has the same sequence. The tag after the gap is the PAM: for the commonly used Cas9 it is any letter followed by GG. The cut position, three letters before the tag, and the rule the readout uses come from Jinek et al. (2012), whose test on one target needed at least 13 matching letters next to the tag and tolerated up to six mismatches at the far end. That rule is a simplification for this toy: real cutting at near-matches varies from site to site, and a mismatch can lower the rate of cutting rather than stop it outright.

What is approved now

In December 2023 the FDA approved Casgevy for sickle cell disease, its first approval of a therapy that uses CRISPR. It was later approved for transfusion-dependent beta thalassaemia too, and in July 2026 the FDA extended both uses to patients aged 2 and over. Casgevy is not an injection of CRISPR. Doctors collect the patient's own blood-forming stem cells and edit them outside the body so that the red blood cells they make carry more fetal haemoglobin, which helps stop the cells sickling. The patient first has full myeloablative conditioning, the high-intensity preparation given before a stem cell transplant, then gets the edited cells back, and they settle in the bone marrow. The trials behind the July 2026 extension were small: 11 children with sickle cell disease, all 8 who could be assessed free of severe pain crises for at least a year, and 15 with thalassaemia, 8 of 9 assessed free of transfusions for a year. The label warns of the chance of edits at places other than the intended one.

Editing cells inside the body is the next step, and it is not approved yet. Intellia's lonvo-z, for hereditary angioedema, a rare swelling disorder, is a single dose meant to switch off one gene for good, KLKB1, and so lower a protein, kallikrein, that drives the attacks. The company says it is under FDA review with a target decision date of 10 March 2027, and that if approved it would be the world's first CRISPR therapy that works inside the body.

Why the germline fight is real

Every approved use is somatic: the edited cells belong to one patient and are not passed on. Heritable editing changes an embryo, an egg or a sperm, so the change is in every cell of the child that results and can be inherited by that child's children. The birth of babies from edited embryos was announced in 2018, and statements on the subject still cite it.

The ISSCR's 2021 guidelines put heritable genome editing in their "not allowed: currently unsafe" category, separate from the category for research that lacks a compelling scientific rationale or is ethically concerning; their 2025 update changed only the section on embryo models. The 2023 international summit on human genome editing concluded that heritable editing "remains unacceptable at this time". In May 2025 three cell and gene therapy groups, ARM, ISCT and ASGCT, called for a moratorium until at least 2035. Their reasons: edited embryos can be mosaic, with some cells carrying the edit and some not, a risk they call high; wrong-place cuts would be inherited; and other ways exist to avoid passing on the conditions it might be used for. The real disagreement sits in the words "currently" and "at this time": whether this is a "not yet" or a "never".

In one breath

Cas9 cuts both DNA strands where a 20-letter guide matches next to a GG tag, and the cell's own repair does the editing, sometimes at a place that only nearly matches. One CRISPR medicine is approved in the US, made by editing a patient's blood stem cells outside the body. Editing embryos for reproduction is off-limits under the ISSCR guidelines and the 2023 summit's conclusion, and the argument now is whether that is temporary.

Where this comes from

  1. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity (Science 337(6096):816-821) linked only, not reproduced
    Martin Jinek, Krzysztof Chylinski, Ines Fonfara, Michael Hauer, Jennifer A. Doudna, Emmanuelle Charpentier · 2012
    pmc.ncbi.nlm.nih.gov/articles/PMC6286148/
  2. Scientific Background on the Nobel Prize in Chemistry 2020: A Tool for Genome Editing linked only, not reproduced
    The Royal Swedish Academy of Sciences (Claes Gustafsson, Nobel Committee for Chemistry) · 2020
    www.nobelprize.org/uploads/2020/10/advanced-chemistryprize2020.pdf
  3. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (news release, 8 December 2023) linked only, not reproduced
    US Food and Drug Administration · 2023
    www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
  4. FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease (news release, 1 July 2026) linked only, not reproduced
    US Food and Drug Administration · 2026
    www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease
  5. Approved Cellular and Gene Therapy Products (list current as of 17 September 2026) linked only, not reproduced
    US Food and Drug Administration, Office of Therapeutic Products · 2026
    www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
  6. Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (press release, 8 September 2026, via BioSpace) linked only, not reproduced
    Intellia Therapeutics, Inc. · 2026
    www.biospace.com/press-releases/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-priority-review-for-lonvoguran-ziclumeran-lonvo-z-for-hereditary-angioedema-hae
  7. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update (Stem Cell Reports 16(6):1398-1408) linked only, not reproduced
    Robin Lovell-Badge, Eric Anthony, Roger A. Barker, Tania Bubela, Ali H. Brivanlou, Melissa Carpenter et al. (ISSCR Guidelines Task Force, 45 authors) · 2021
    pmc.ncbi.nlm.nih.gov/articles/PMC8190668/
  8. Guidelines for Stem Cell Research and Clinical Translation (August 2025 update, version 1.2) linked only, not reproduced
    International Society for Stem Cell Research · 2025
    www.isscr.org/resources/guidelines-for-stem-cell-research
  9. Statement from the Organising Committee of the Third International Summit on Human Genome Editing linked only, not reproduced
    Organising Committee of the Third International Summit on Human Genome Editing (Royal Society, Academy of Medical Sciences, US National Academies, The World Academy of Sciences) · 2023
    royalsociety.org/news/2023/03/statement-third-international-summit-human-genome-editing/
  10. International Call for a 10-Year Moratorium on Heritable Human Genome Editing linked only, not reproduced
    Alliance for Regenerative Medicine, International Society for Cell & Gene Therapy, American Society of Gene & Cell Therapy · 2025
    www.asgct.org/advocacy/policy-statements/international-call-for-a-10-year-moratorium-on-heritable-human-genome-editing-a-multi-stakeholder-initiative-to-ensure-safe-and-responsible-use-of-genetic-technologies-may-2025